CAPELLA: Week 26 Results of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced Patients

July 18-21, 2021; Virtual
In patients with multidrug-resistant HIV-1 infection, lenacapavir in combination with an optimized background regimen demonstrated a high rate of virologic suppression, a clinically meaningful increase in CD4+ cell count, and no discontinuation of study therapy due to adverse events through 26 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 249 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

From Dr. Eric Daar and CCO, slides covering new data from IAS 2021 expanding our understanding of the adverse event profiles of specific ART regimens

Eric S. Daar, MD Released: September 22, 2021

Clinical Care Options’ (CCO) commentary on patient education for people living with HIV during the COVID-19 pandemic

Sharon L. Walmsley, MSc, MD, FRCPC Released: September 22, 2021

From Dr. Eric S. Daar and Clinical Care Options (CCO), expert discussion on how new data from IAS 2021 expand our understanding of adverse events with specific ART regimens

Eric S. Daar, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 22, 2021 Expired: September 21, 2022

Clinical Care Options (CCO) expert commentary by Dr Babafemi Taiwo on how the latest data from the AMBITION-cm trial will affect the treatment of patients with HIV in Africa

Babafemi Taiwo, MBBS Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue